Array’s losses increase to $6.3M
The Daily Times-Call
BOULDER — Array BioPharma Inc., with facilities in Longmont and Boulder, reported an increase in its net loss for the most recent quarter.
For the second quarter of fiscal year 2004, Array reported a net loss of $6.3 million, or 22 cents per diluted share, on total revenue of $7.6 million.
During the same quarter of fiscal 2003, Array had reported a net loss of $2.9 million, or 10 cents per share, on revenue of $9.5 million.
During the recent quarter, Array signed agreements with AstraZeneca and Genentech which involve outlicensing and co-developing proprietary oncology products, developed by Array, for the treatment of cancer patients.